Endo USA, INC., a Mallinckrodt-endo Company

pharmaceutical manufacturing

Based in PA

🤖

AI Overview

With $4.1M in lobbying spend across 53 quarterly filings, Endo USA, INC., a Mallinckrodt-endo Company is a significant lobbying presence.

$4.1M
Total Lobbying Spend
53
Quarterly Filings
1
Lobbying Firms Used
5
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$540K
2019$990K
2020$700K
2021$630K
2022$530K
2023$280K
2024$210K
2025$230K

Lobbying Firms

FOLEY & LARDNER LLP

What They Lobby For

  • FDA Issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market
  • FDA Issues Related to Compounding
  • FDA issues related to compounding; issues related to Medicare reimbursement of pharmaceuticals.
  • FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market; drug pricing issues
  • FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market.
  • Issues related to Medicare reimbursement of pharmaceuticals.
  • Issues related to generic pharmaceuticals; issues related to Medicare reimbursement of pharmaceuticals.
  • Issues related to taxation; Issues related to Medicare reimbursement of pharmaceuticals.
  • Issues related to taxation; issues related to Medicare reimbursement of pharmaceuticals.
  • Issues related to domestic manufacturing; issues related to Strategic National Stockpile; issues related to Medicare reimbursement of pharmaceuticals.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.